{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:16:42Z","timestamp":1789759002213,"version":"4.0.1"},"reference-count":42,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,6,27]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>PF-06747143, a novel CXCR4 antagonist IgG1 Ab, mobilizes malignant cells from the BM and induces their death via Fc-effector function. PF-06747143 reduces tumor burden in NHL, AML, and MM models, both as a monotherapy or in combination with standard-of-care agents.<\/jats:p>","DOI":"10.1182\/bloodadvances.2016003921","type":"journal-article","created":{"date-parts":[[2017,6,21]],"date-time":"2017-06-21T20:40:20Z","timestamp":1498077620000},"page":"1088-1100","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":48,"title":["A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies"],"prefix":"10.1182","volume":"1","author":[{"given":"Shu-Hui","family":"Liu","sequence":"first","affiliation":[{"name":"Oncology Research & Development, Pfizer Worldwide Research & Development, South San Francisco, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Gu","sequence":"additional","affiliation":[{"name":"Oncology Research & Development,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Pascual","sequence":"additional","affiliation":[{"name":"Oncology Research & Development,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengming","family":"Yan","sequence":"additional","affiliation":[{"name":"Oncology Research & Development,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Hallin","sequence":"additional","affiliation":[{"name":"Oncology Research & Development,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Zhang","sequence":"additional","affiliation":[{"name":"Oncology Research & Development,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conglin","family":"Fan","sequence":"additional","affiliation":[{"name":"Oncology Research & Development,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlian","family":"Wang","sequence":"additional","affiliation":[{"name":"Pharmacokinetics-Dynamics-Metabolism, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Lam","sequence":"additional","affiliation":[{"name":"Pharmacokinetics-Dynamics-Metabolism, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Spilker","sequence":"additional","affiliation":[{"name":"Pharmacokinetics-Dynamics-Metabolism, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolla","family":"Yafawi","sequence":"additional","affiliation":[{"name":"Drug Safety Research & Development, Pfizer Worldwide Research & Development, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Blasi","sequence":"additional","affiliation":[{"name":"Drug Safety Research & Development, Pfizer Worldwide Research & Development, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Simmons","sequence":"additional","affiliation":[{"name":"Oncology Research & Development,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanni","family":"Huser","sequence":"additional","affiliation":[{"name":"Oncology Research & Development,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Hsien","family":"Ho","sequence":"additional","affiliation":[{"name":"Oncology Research & Development, Pfizer Worldwide Research & Development, South San Francisco, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Lindquist","sequence":"additional","affiliation":[{"name":"Oncology Research & Development, Pfizer Worldwide Research & Development, South San Francisco, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas-Toan","family":"Tran","sequence":"additional","affiliation":[{"name":"Oncology Research & Development, Pfizer Worldwide Research & Development, South San Francisco, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyothirmayee","family":"Kudaravalli","sequence":"additional","affiliation":[{"name":"Oncology Research & Development, Pfizer Worldwide Research & Development, South San Francisco, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Tyan","family":"Ma","sequence":"additional","affiliation":[{"name":"Oncology Research & Development, Pfizer Worldwide Research & Development, South San Francisco, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen","family":"Jimenez","sequence":"additional","affiliation":[{"name":"Oncology Research & Development,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishita","family":"Barman","sequence":"additional","affiliation":[{"name":"Oncology Research & Development, Pfizer Worldwide Research & Development, South San Francisco, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Brown","sequence":"additional","affiliation":[{"name":"Oncology Research & Development, Pfizer Worldwide Research & Development, South San Francisco, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherman Michael","family":"Chin","sequence":"additional","affiliation":[{"name":"Oncology Research & Development, Pfizer Worldwide Research & Development, South San Francisco, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Costa","sequence":"additional","affiliation":[{"name":"Oncology Research & Development, Pfizer Worldwide Research & Development, South San Francisco, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Shelton","sequence":"additional","affiliation":[{"name":"Oncology Research & Development, Pfizer Worldwide Research & Development, South San Francisco, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tod","family":"Smeal","sequence":"additional","affiliation":[{"name":"Oncology Research & Development,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria R.","family":"Fantin","sequence":"additional","affiliation":[{"name":"Oncology Research & Development,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Pernasetti","sequence":"additional","affiliation":[{"name":"Oncology Research & Development,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2017,6,21]]},"reference":[{"issue":"2","key":"2019111608400121900_B1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0014-5793(98)00359-7","article-title":"Genomic organization and promoter characterization of human CXCR4 gene","volume":"426","author":"Caruz","year":"1998","journal-title":"FEBS Lett"},{"issue":"6685","key":"2019111608400121900_B2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/31269","article-title":"Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development","volume":"393","author":"Zou","year":"1998","journal-title":"Nature"},{"issue":"2","key":"2019111608400121900_B3","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1182\/blood-2006-05-024844","article-title":"CXCR4 is a prognostic marker in acute myelogenous leukemia","volume":"109","author":"Spoo","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2019111608400121900_B4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/leu.2008.299","article-title":"CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers","volume":"23","author":"Burger","year":"2009","journal-title":"Leukemia"},{"issue":"5","key":"2019111608400121900_B5","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2010.31.0904","article-title":"Leukemia stem cells and microenvironment: biology and therapeutic targeting","volume":"29","author":"Konopleva","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111608400121900_B6","doi-asserted-by":"crossref","first-page":"e98194","DOI":"10.1371\/journal.pone.0098194","article-title":"Decreased expression of CXCR4 chemokine receptor in bone marrow after chemotherapy in patients with non-Hodgkin lymphomas is a good prognostic factor","volume":"9","author":"Mazur","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"2019111608400121900_B7","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/cncr.22510","article-title":"Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype","volume":"109","author":"Konoplev","year":"2007","journal-title":"Cancer"},{"issue":"3","key":"2019111608400121900_B8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.cell.2005.02.034","article-title":"Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1\/CXCL12 secretion","volume":"121","author":"Orimo","year":"2005","journal-title":"Cell"},{"issue":"11","key":"2019111608400121900_B9","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1158\/1078-0432.CCR-09-2329","article-title":"CXCL12 (SDF-1)\/CXCR4 pathway in cancer","volume":"16","author":"Teicher","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2019111608400121900_B10","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2005-08-3182","article-title":"CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment","volume":"107","author":"Burger","year":"2006","journal-title":"Blood"},{"issue":"5","key":"2019111608400121900_B11","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1189\/jlb.1002495","article-title":"Stromal cell-derived factor-1\/CXCL12 directly enhances survival\/antiapoptosis of myeloid progenitor cells through CXCR4 and G(alpha)i proteins and enhances engraftment of competitive, repopulating stem cells","volume":"73","author":"Broxmeyer","year":"2003","journal-title":"J Leukoc Biol"},{"issue":"1","key":"2019111608400121900_B12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.7150\/thno.4621","article-title":"Innate immunity derived factors as external modulators of the CXCL12-CXCR4 axis and their role in stem cell homing and mobilization","volume":"3","author":"Ratajczak","year":"2013","journal-title":"Theranostics"},{"issue":"9","key":"2019111608400121900_B13","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1158\/1541-7786.MCR-13-0114","article-title":"Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML","volume":"11","author":"Sison","year":"2013","journal-title":"Mol Cancer Res"},{"issue":"2","key":"2019111608400121900_B14","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10549-008-9921-8","article-title":"Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC)","volume":"113","author":"Holm","year":"2009","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"2019111608400121900_B15","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1158\/1535-7163.MCT-06-0228","article-title":"Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias","volume":"5","author":"Zeng","year":"2006","journal-title":"Mol Cancer Ther"},{"issue":"24","key":"2019111608400121900_B16","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.1182\/blood-2008-05-158311","article-title":"Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML","volume":"113","author":"Zeng","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2019111608400121900_B17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejca.2012.05.005","article-title":"A review on CXCR4\/CXCL12 axis in oncology: no place to hide","volume":"49","author":"Domanska","year":"2013","journal-title":"Eur J Cancer"},{"issue":"24","key":"2019111608400121900_B18","doi-asserted-by":"crossref","first-page":"6206","DOI":"10.1182\/blood-2008-06-162123","article-title":"Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100","volume":"113","author":"Nervi","year":"2009","journal-title":"Blood"},{"issue":"10","key":"2019111608400121900_B19","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1080\/10428190903150847","article-title":"Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to imatinib and nilotinib","volume":"50","author":"Dillmann","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"2019111608400121900_B20","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.3882.3882","article-title":"Mobilization of blasts and leukemia stem cells by anti-CXCR4 antibody BMS-936564 (MDX 1338) in patients with relapsed\/refractory acute myeloid leukemia [abstract]","volume":"122","author":"Chien","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2019111608400121900_B21","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1128\/AAC.44.6.1667-1673.2000","article-title":"Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers","volume":"44","author":"Hendrix","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2019111608400121900_B22","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1097\/01.qai.0000137371.80695.ef","article-title":"Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection","volume":"37","author":"Hendrix","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"17","key":"2019111608400121900_B23","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1182\/blood-2011-10-383406","article-title":"A phase 1\/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia","volume":"119","author":"Uy","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2019111608400121900_B24","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1158\/1535-7163.MCT-14-0850","article-title":"Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models","volume":"14","author":"Peng","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"13","key":"2019111608400121900_B25","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1158\/1078-0432.CCR-13-2686","article-title":"A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer","volume":"20","author":"Galsky","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2019111608400121900_B26","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1158\/1078-0432.CCR-13-1302","article-title":"The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma","volume":"20","author":"Peled","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"21","key":"2019111608400121900_B27","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.4190.4190","article-title":"BMS-936564 (anti-CXCR4 antibody) induces specific leukemia cell mobilization and objective clinical responses in CLL patients treated under a phase I clinical trial [abstract]","volume":"122","author":"Kashyap","year":"2013","journal-title":"Blood"},{"issue":"21","key":"2019111608400121900_B28","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.3483.3483","article-title":"Phase 1b study of the novel anti-CXCR4 antibody ulocuplumab (BMS-936564) in combination with lenalidomide plus low-dose dexamethasone, or with bortezomib plus dexamethasone in subjects with relapsed or refractory multiple myeloma [abstract]","volume":"124","author":"Ghobrial","year":"2014","journal-title":"Blood"},{"issue":"21","key":"2019111608400121900_B29","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.386.386","article-title":"Targeting the CXCR4 pathway: safety, tolerability and clinical activity of ulocuplumab (BMS-936564), an anti-CXCR4 antibody, in relapsed\/refractory acute myeloid leukemia [abstract]","volume":"124","author":"Becker","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2019111608400121900_B30","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd3365","article-title":"Advances in the assessment and control of the effector functions of therapeutic antibodies","volume":"10","author":"Jiang","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"2019111608400121900_B31","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.18632\/oncotarget.6465","article-title":"Ulocuplumab (BMS-936564\/MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway","volume":"7","author":"Kashyap","year":"2016","journal-title":"Oncotarget"},{"issue":"1-2","key":"2019111608400121900_B32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10428190009053534","article-title":"Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management","volume":"39","author":"Porcu","year":"2000","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2019111608400121900_B33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00002030-200301030-00006","article-title":"Platelet- and megakaryocyte-derived microparticles transfer CXCR4 receptor to CXCR4-null cells and make them susceptible to infection by X4-HIV","volume":"17","author":"Rozmyslowicz","year":"2003","journal-title":"AIDS"},{"issue":"1","key":"2019111608400121900_B34","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/cts.12111","article-title":"Rituximab for non-Hodgkin\u2019s lymphoma: a story of rapid success in translation","volume":"7","author":"Harrison","year":"2014","journal-title":"Clin Transl Sci"},{"issue":"6","key":"2019111608400121900_B35","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.blre.2015.06.001","article-title":"Treatment for patients with newly diagnosed multiple myeloma in 2015","volume":"29","author":"Mateos","year":"2015","journal-title":"Blood Rev"},{"issue":"suppl 1","key":"2019111608400121900_B36","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1179\/102453312X13336169154971","article-title":"Multiple myeloma: treatment evolution","volume":"17","author":"San Miguel","year":"2012","journal-title":"Hematology"},{"issue":"2-3","key":"2019111608400121900_B37","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/02841860151116321","article-title":"A systematic overview of chemotherapy effects in acute myeloid leukaemia","volume":"40","author":"Kimby","year":"2001","journal-title":"Acta Oncol"},{"issue":"1","key":"2019111608400121900_B38","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1182\/blood-2013-10-529313","article-title":"Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants","volume":"123","author":"Galanis","year":"2014","journal-title":"Blood"},{"issue":"24","key":"2019111608400121900_B39","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1182\/blood-2011-09-380410","article-title":"Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features","volume":"119","author":"Azab","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2019111608400121900_B40","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/leu.2013.201","article-title":"CXCR4-SERINE339 regulates cellular adhesion, retention and mobilization, and is a marker for poor prognosis in acute myeloid leukemia","volume":"28","author":"Brault","year":"2014","journal-title":"Leukemia"},{"issue":"18","key":"2019111608400121900_B41","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1182\/blood-2008-10-186668","article-title":"CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy","volume":"113","author":"Azab","year":"2009","journal-title":"Blood"},{"key":"2019111608400121900_B42","doi-asserted-by":"crossref","first-page":"16228","DOI":"10.1038\/srep16228","article-title":"Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4\/CXCL12 axis","volume":"5","author":"Li","year":"2015","journal-title":"Sci Rep"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/15\/1088\/878520\/advances003921.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/15\/1088\/878520\/advances003921.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T08:40:25Z","timestamp":1573893625000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/1\/15\/1088\/15732\/A-novel-CXCR4-antagonist-IgG1-antibody-PF06747143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,21]]},"references-count":42,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2017,6,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2016003921","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,21]]}}}